Corteva rated 'Buy' with expected 3% annual growth and margin expansion through 2029

Corteva, Inc. has been rated 'Buy' due to its strong growth prospects and profitability improvements. The company aims for over 3% annual revenue growth from 2026 to 2029, outpacing the global crop protection industry. This growth is supported by portfolio enhancements and a shift towards higher-margin biological products. Additionally, Corteva expects a 150 basis points expansion in EBITDA margin and a 6% EBITDA compound annual growth rate during this period, driven by cost reductions and strategic portfolio changes.

Corteva's stock price stands at USD 13.68 with a market cap of $9.64 billion as of Oct 09, 2026, 15:41 WIB on Pluang, where all order activity is currently buy. Despite a slight 0.51% dip in one day, the company offers a dividend yield of 4.98%, highlighting its appeal to income-focused investors. This trading context complements the positive growth and margin outlook detailed in the news.